Cresco Labs (CRLBF) Asset Writedowns and Impairment (2020 - 2026)

Cresco Labs has reported Asset Writedowns and Impairment for 7 years, with the latest figure at $741000.0 in Q1 2026.

• For the quarter ending Q1 2026, Asset Writedowns and Impairment fell 17.85% year-over-year to $741000.0; the trailing twelve-month figure through Mar 2026 stood at $104.9 million (up 6353.87% YoY), and the FY2025 full-year result was -$1.2 million, down 150.22% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $741000.0, down from $93.5 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $139.4 million in Q4 2022, with the low at -$2.5 million in Q2 2024.
• Historically, Asset Writedowns and Impairment has averaged $25.0 million across 5 years, with a median of $1.2 million in 2022.
• Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment surged 23147.94% — and 2024, when it plunged 112.59%.
• Cresco Labs' Asset Writedowns and Impairment stood at $139.4 million in 2022, then plunged by 99.98% to $24000.0 in 2023, then tumbled by 337.5% to -$57000.0 in 2024, then jumped by 164084.21% to $93.5 million in 2025, then plunged by 99.21% to $741000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $741000.0 (Q1 2026), $93.5 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.